The last few decades have witnessed an acceleration in the discovery and development of therapeutic antibodies.

Respiratory syncytial virus (RSV) has recently gained much attention due to the approval of several drugs this year.On May 3, 2023, the U.S. Food and Drug Administration (FDA) authorized Arexvy, the first RSV vaccine for use in the United States.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.